Please login to the form below

Not currently logged in
Email:
Password:

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

He takes on the role of chief executive officer

Holostem Terapie Avanzate Dr Richard JonesModena, Italy-based Holostem Terapie Avanzate has appointed Dr Richard Jones as its chief executive officer.

Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year.

He brings over two decades of industry experience to the position, including from Novartis, where he was vice president and medicines commercialisation leader for haematology and global oncology.

Prior to this, Dr Jones served as vice president, global haematology medicines leader at GlaxoSmithKline, and has also held posts at Genzyme and Shire.

Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.

“He brings a unique combination of international and rare disease expertise, crucial for this stage of Holostem's evolution.

“We look forward to working with Richard on the continued growth of the company's development and the realisation of the potential of the technology platform.”

2nd February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...